BeOne Medicines is building the world's leading oncology company driven by scientific excellence and exceptional speed to reach more patients than ever before. With a global presence spanning 6 continents and over 45 office locations worldwide, the company employs approximately 12,000 people including 1,200+ research team members. BeOne Medicines advances a broad and deep pipeline of cancer treatments, having initiated 175+ clinical trials globally and enrolling 30,000+ patients. The company has achieved regulatory approval across 75+ countries for three internally developed medicines, demonstrating its commitment to delivering innovative therapies to patients worldwide.
The company's core values - Patients First, Driving Excellence, Bold Ingenuity, and Collaborative Spirit - guide its mission to transform how the world fights cancer. BeOne Medicines focuses on both hematology and solid tumors, pioneering approaches including protein degradation with CDACs and antibody drug conjugates. As a publicly-traded company listed on NASDAQ, HKEX, and SSE exchanges, BeOne combines global reach with local expertise, conducting clinical trials in 45+ countries and regions to address unmet medical needs in oncology. The company culture emphasizes non-hierarchical teamwork and challenges the status quo to deliver scientific breakthroughs once thought impossible.